Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $1.3 million.

  • Cartesian Therapeutics' Capital Expenditures fell 7654.75% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 3295.08%. This contributed to the annual value of $9.1 million for FY2024, which is 431407.77% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Capital Expenditures stood at $1.3 million for Q3 2025, which was down 7654.75% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Capital Expenditures registered a high of $5.5 million during Q3 2024, and its lowest value of $12000.0 during Q2 2023.
  • Its 5-year average for Capital Expenditures is $919277.8, with a median of $445500.0 in 2022.
  • In the last 5 years, Cartesian Therapeutics' Capital Expenditures tumbled by 8787.88% in 2023 and then soared by 1887500.0% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Capital Expenditures (Quarter) stood at $278000.0 in 2021, then dropped by 24.1% to $211000.0 in 2022, then tumbled by 69.67% to $64000.0 in 2023, then soared by 1001.56% to $705000.0 in 2024, then skyrocketed by 83.26% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.6 million for Q2 2025, and $1.1 million during Q1 2025.